Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.270 million which missed the analyst consensus estimate of $2.420 million by 6.20 percent. This is a 0.70 percent decrease over sales of $2.286 million the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。